At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
In Brief
A Phase 4 clinical trial evaluating Apremilast for Psoriasis and Cardiovascular Diseases. Completed, enrolled 70 participants across 7 sites.
Detailed Summary
The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Cardiovascular Diseases
CountriesUnited States
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartApr 2017
Primary CompletionAug 2021
TodayJul 2026
First PostedMar 17, 2017
Enrollment StartApr 24, 2017
Primary CompletionAug 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.3 years ago
Interventions
Apremilastdrug
Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.